Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Area of Science:

• Dermatology
• Oncology

Background:

• Basal cell carcinoma (BCC) is the most prevalent skin malignancy.
• While metastasis is rare, recurrent or multiple BCCs pose significant management challenges and morbidity.
• Risk assessment is crucial for guiding treatment decisions in BCC management.

Purpose of the Study:

• To present the NCCN Guidelines for Basal Cell Skin Cancer.
• To provide recommendations for selecting appropriate management strategies for BCC.
• To guide clinicians on utilizing various therapeutic modalities based on patient and disease factors.

Main Methods:

• Review and synthesis of current evidence and expert consensus on BCC management.
• Development of evidence-based recommendations for treatment selection.
• Inclusion of guidance on surgical, radiation, superficial, and systemic therapies.

Main Results:

• The guidelines offer a framework for choosing among surgical options based on patient, lesion, and disease characteristics.
• Recommendations are provided for the use of radiation therapy as an alternative or adjuvant treatment.
• Guidance is included on the application of superficial therapies and emerging hedgehog pathway inhibitors for advanced BCC.

Conclusions:

• The NCCN Guidelines provide comprehensive recommendations for the management of Basal Cell Skin Cancer.
• Effective management requires a tailored approach considering multiple factors and available treatment options.
• The guidelines incorporate recent advancements, including FDA-approved hedgehog pathway inhibitors for advanced BCC.